Xeljanz for Rheumatoid arthritis: every route to paying for it

The routes, in order

1. 1

   Why this drug and this condition are paired

   Moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers.

   From the Indications and Usage text of the drug's FDA label. A label naming a condition is not a statement that the drug is approved, effective or covered for you.

   Label on openFDA, read 2026-11-10 · receipt

2. 2

   Medicare Part D: the yearly out-of-pocket threshold

   Found in our data
   CMS prints the Part D out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026).

   A benefit parameter of the standard Part D benefit. It applies to covered drugs under plan rules and is not a prediction of what you will pay. Your plan's formulary decides whether this drug is covered: check a formulary.

   CMS Table V-2, read 2026-11-08

3. 3

   Medicare negotiated price

   Found in our data
   CMS has selected this drug for prices effective 2028-01-01. No price is published yet.

   CMS negotiated prices, read 2026-11-06

4. 4

   Manufacturer and foundation programs

   Found in our data
   • Pfizer RxPathways receipt no new patients starting July 1, 2026 Limited the program's own page, read 2026-11-07
   • RA Medication Assistance (Multiple Programs) status not recorded

   A status is what the program's page says about taking applications, not whether you qualify. Each program has its own eligibility rules.

5. 5

   Charitable funds for Rheumatoid arthritis

   Found in our data
   We hold 1 fund for Rheumatoid arthritis: 0 open and 1 not open, read 2026-11-08.

   Every fund, with its award level, insurance supported and source, is on the Rheumatoid arthritis page. A fund pays for a condition's costs, not necessarily this drug.

6. 6

   Clinical trial access

   Found in our data
   ClinicalTrials.gov lists 28 recruiting interventional trials that name this ingredient (read 2026-11-07).

   A trial is research, not treatment access for everyone, and a listing is not a recommendation.

   ClinicalTrials.gov, read 2026-11-07 · receipt

Questions